Major Licensing Deals and M&A
Executive Summary - June 16 to June 23, 2026
After two consecutive M&A-led weeks with no major out-license, the cross-border (China-out) engine restarted in-window. Antengene (China) granted K2 Therapeutics - a US asset company established by MPM BioImpact - an exclusive license to ATG-106, a preclinical CDH6xCD3 bispecific T-cell engager (TCE) for solid tumors, with exclusive rights outside Greater China. Economics: about $20M upfront and near-term (cash plus a minority equity stake in a newly formed K2 subsidiary), up to $960.5M in development, regulatory and sales milestones, and tiered royalties. The deal also grants K2 an option on a second, undisclosed Antengene bispecific TCE on substantially similar terms (about $20M plus up to $960.5M on exercise).
Two US bolt-on acquisitions rounded out the week. Eli Lilly agreed to acquire 4E Therapeutics (terms undisclosed) for its oral MNK-inhibitor non-opioid pain pipeline, and Biogen agreed to acquire RayThera for up to $1B (upfront plus milestones) to expand its immunology pipeline. As always, BD professionals should anchor to near-term cash and de-risking; this week paired an early-stage China-out license with two preclinical-weighted US acquisitions.
Licensing & Partnering - June 16 to June 23, 2026
| Date | Licensee | Licensor / Asset | Economics | Key Terms & Strategic Notes |
|---|---|---|---|---|
| Jun 22, 2026 (announced) | K2 Therapeutics (US; MPM BioImpact-established) | Antengene (China) - ATG-106 (CDH6xCD3 bispecific TCE, preclinical, solid tumors) | ~$20M upfront + near-term (cash + minority equity stake); up to $960.5M milestones; tiered royalties | K2 obtains exclusive rights to develop and commercialize ATG-106 globally ex-Greater China. The deal also grants K2 an option on an undisclosed Antengene bispecific TCE (an additional ~$20M plus up to $960.5M on exercise). A China-out license of an early-stage AnTenGager TCE; structure pairs modest cash with a minority equity stake in a purpose-built K2 asset company. |
M&A Transactions - June 16 to June 23, 2026
| Date | Acquirer | Target | Deal Value | Strategic Rationale |
|---|---|---|---|---|
| Jun 16, 2026 (announced) | Eli Lilly | 4E Therapeutics (US) | Undisclosed | Adds a pipeline of orally available MNK inhibitors for chronic pain via a non-opioid mechanism (the MNK-eIF4E pathway in peripheral sensory neurons). Lead candidate 4ET1103 was the first MNK inhibitor to enter human trials, with a favorable Phase 1 safety profile. Continues Lilly's non-opioid pain build-out following its 2025 acquisition of SiteOne Therapeutics. |
| Jun 17, 2026 (announced) | Biogen | RayThera (US) | Up to $1B (upfront + milestones) | Adds a portfolio of preclinical small-molecule immunology and anti-inflammatory assets for immune-mediated conditions; the lead candidate is expected to enter Phase 1 in early Q3 2026. Biogen's second acquisition of 2026; the transaction is expected to close in Q3 2026. |
Weekly Takeaways
- The China-out engine restarted in-window: after two M&A-led weeks, Antengene's ATG-106 deal with MPM-backed K2 (about $20M up / up to ~$980M total) put a China-origin bispecific TCE back on the board, and reinforced the structuring trend of pairing modest cash with an equity stake in a purpose-built asset company.
- Early-stage assets are trading: ATG-106 (preclinical) and RayThera (preclinical immunology) both changed hands this week - a reminder that buyer appetite now reaches upstream of clinical proof when the target biology or platform is differentiated.
- Bispecific T-cell engagers remain a top China-out modality; the CDH6xCD3 ATG-106 adds to the run of China-origin bispecific and TCE assets seeking Western development partners.
- Upfront compression persists: about $20M upfront-plus-near-term against an ~$980M total package is consistent with the low single-digit upfront-to-total ratios typical of early-stage China-out portfolio licensing.
- Non-opioid pain stays an active acquisition theme: Lilly's 4E buy (undisclosed terms) deepens a franchise it has built through bolt-ons.
- What to watch next week: the BLA filings flagged this week (MoonLake's sonelokimab in HS by end-September; tebipenem US availability by year-end), follow-through on the AnTenGager option, and whether the China-out cadence holds into July.
Global Biomedicine Highlights
Clinical Readouts & Regulatory - June 16 to June 23, 2026
June 17, 2026 - FDA Approves Utebzi (tebipenem pivoxil), the First Oral Carbapenem Antibiotic, for Complicated UTIs (Spero / GSK)
The FDA approved Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic cleared in the United States, for adults with complicated urinary tract infections (cUTI) including pyelonephritis. Developed by Spero Therapeutics and partner GSK, the approval rests on the 1,690-patient Phase 3 PIVOT-PO trial, in which oral tebipenem pivoxil achieved a 58.5% test-of-cure success rate versus 60.2% for intravenous imipenem-cilastatin - meeting the non-inferiority bar and providing an oral alternative to IV-only carbapenems for resistant infections. US availability is anticipated by the end of 2026.
BD Implication: A first-in-class oral reformulation of a previously IV-only mechanism underscores the durable commercial value of route-of-administration innovation - a recurring thesis for Western buyers evaluating China-origin oral small molecules and reformulation platforms.
June 21, 2026 - MoonLake Sonelokimab Phase 3 VELA: Week 52 Data Show Deep, Durable Responses in Hidradenitis Suppurativa
MoonLake Immunotherapeutics reported one-year (Week 52) results from its Phase 3 VELA program of sonelokimab, a Nanobody targeting IL-17A and IL-17F, in moderate-to-severe hidradenitis suppurativa (HS). 67.2% of patients achieved HiSCR75, 33.1% achieved HiSCR100 (complete response), and 26.0% achieved IHS4-100, with a 15.0-point mean improvement in HiSQOL and no new safety signals. MoonLake plans to file a US Biologics License Application in HS by the end of September 2026.
BD Implication: Deep-remission endpoints (HiSCR100 and IHS4-100) are raising the efficacy bar in immuno-dermatology and reinforce IL-17A/F co-targeting as a competitive axis - directly relevant to the IL-17 and broader immunology assets among China-origin biologics seeking Western partners.
June 22, 2026 - Definium DT120 Phase 3 Emerge: Single-Dose Lysergide ODT Meets Primary Endpoint in Major Depressive Disorder
Definium Therapeutics announced positive topline results from the Phase 3 Emerge study of DT120 (lysergide) orally disintegrating tablet - a single 100 mcg dose - in adults with major depressive disorder (MDD). The study met its primary endpoint with an 8.1-point placebo-adjusted reduction on the Montgomery-Asberg Depression Rating Scale (MADRS) at Week 6 (p<0.0001) and a 7.3-point placebo-adjusted reduction at Week 12 (p<0.0001, a key secondary). DT120 was generally well tolerated, with no serious adverse events and no suicidality signal; 99% of treatment-emergent adverse events were mild to moderate.
BD Implication: A positive pivotal readout for a single-administration psychedelic-derived antidepressant validates a CNS category that has drawn cautious partnering interest, and points to durable, low-frequency dosing as a differentiator that Western buyers and funds will weigh in CNS licensing - including for China-origin neuro assets.
Calendar note: readouts reviewed this week that dated outside the June 16-23 window were omitted accordingly, including Amgen's TEPEZZA subcutaneous on-body-injector Phase 3 in thyroid eye disease (topline April 2026) and ASCO-period oncology and obesity readouts.
Job Postings
Executive and senior-level openings across C-suite, BD&L, R&D leadership, manufacturing, and medical affairs - spanning both U.S. and China-based employers - are tracked on the dedicated Job Board. BD&L talent searches frequently pair with the buyer and fund mandates on the Opportunity Board below.
View the Job BoardBD&L Opportunity Board
Active In-Licensing Mandates (Standing)
No new buyer in-licensing mandates were registered this week; the full standing board carried forward from prior weeks is listed below. All are US/EU buyer or fund mandates with ex-China or global rights preferred unless noted, and new assets matching any mandate can be routed via the BD inbox at any time. Two standing service and capital offerings (an ADC CDMO and an ADC investment mandate) appear in Section 4.4.
Hematology Diseases - Polycythemia Vera, Von Willebrand Disease, Warm AIHA
US/EU companies are in-licensing programs across three hematology indications: polycythemia vera (PV), von Willebrand disease (VWD), and warm autoimmune hemolytic anemia (warm AIHA). Large molecules, small molecules, siRNA, and peptides are all acceptable; preclinical stage is acceptable. Ex-China / global rights preferred.
Target-Interest Mandates - 16 New Targets
US/EU companies are in-licensing programs against the following targets (mechanism in parentheses where specified); preclinical stage is acceptable: CHRM4 inhibitor; COX / 5-LOX inhibitor; FcRn inhibitor; IFN-gamma inhibitor; JAK2 V617F mutant-selective inhibitor; LNK inhibitor; AKT1 inhibitor; APJ antagonist; BMP9 recombinant protein (mimic endogenous BMP9); CALR mutant-selective inhibitor; matriptase-2 inhibitor; plasminogen inhibitor; protein S inhibitor; SF3B1 splicing modulator; TIE2 inhibitor; and TPO receptor / MPL inhibitor. Ex-China / global rights preferred.
Small-Molecule Weight Loss via Energy Expenditure
US/EU companies are in-licensing small-molecule weight-loss programs, oral formulations preferred. They are not seeking traditional appetite-suppression mechanisms; rather, they want weight loss achieved by boosting energy metabolism or energy expenditure. Preclinical stage is acceptable. Ex-China / global rights preferred.
Rare & Special Movement Disorders, Motor Neuron Disease, Rare Epilepsy
US/EU companies are in-licensing novel, potentially disease-modifying therapies for rare and special movement disorders, motor neuron disease, and rare epilepsy. Projects at any stage are welcome and modality is open. Ex-China / global rights preferred.
TRAIL Agonist - Target Interest
US/EU companies are in-licensing TRAIL-agonist programs. Assets from preclinical candidate (PCC) stage through Phase II can be considered; indication flexible. Ex-China / global rights preferred.
Oligonucleotide & Small Nucleic Acid Programs (Fund Mandate)
A well-established US/EU fund is seeking siRNA, antisense oligonucleotide, and small nucleic acid programs. No restriction on disease area; preclinical assets are acceptable. Ex-China / global rights preferred.
Cardiovascular & Kidney Disease - Multi-Modality
US/EU companies are in-licensing cardiovascular and kidney disease programs across modalities - small molecules, large molecules, siRNA, peptides, and antisense oligonucleotides. Preclinical assets are acceptable. Ex-China / global rights preferred.
KRAS G12V - Target-Specific (Oncology)
US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.
AL Amyloidosis - Disease-Area Mandate
US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.
ANCA-Associated Vasculitis (GPA, MPA, EGPA)
US/EU buyer disease-area mandate for ANCA-associated vasculitis across GPA, MPA, and EGPA. Small molecule or biologic; PCC stage or later. Mechanism open.
Anemia of Chronic Kidney Disease
US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.
Anemia of Inflammatory Bowel Disease
US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.
CCR3 Antagonist - Target Interest
US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAG1 Agonist - Target Interest
US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.
ENTPD1 / CD39 Antagonist - Target Interest
US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.
Geographic-Arbitrage: Chinese Phase I/IIa Assets
Fund invests in Chinese-originated Phase I or IIa assets, re-runs / extends clinical development in EU/US (Western data is more readily accepted by MNCs), then out-licenses or sells to MNCs.
Newco Formation around Phase III Programs
Large European/American funds building purpose-built Newcos around Phase III clinical-stage programs in Oncology, Autoimmune, and CNS. Asset contributable or out-licensable into a fund-backed Newco structure.
Sourcing Cross-Reference - What to Flag into Biolink
For readers with assets or intros that match the mandates above, the following cross-reference summarizes what Biolink can route directly to the relevant buyer or fund.
| Buyer Mandate | What to Source / Flag to Biolink |
|---|---|
| Hematology Diseases (PV, VWD, warm AIHA) | Programs for polycythemia vera, von Willebrand disease, or warm autoimmune hemolytic anemia; large or small molecule, siRNA, or peptide; preclinical acceptable; ex-China / global rights. |
| Target-Interest - 16 New Targets | Programs against CHRM4, COX/5-LOX, FcRn, IFN-gamma, JAK2 V617F (mutant-selective), LNK, AKT1, APJ, BMP9 (recombinant), CALR (mutant-selective), matriptase-2, plasminogen, protein S, SF3B1, TIE2, or TPO-R/MPL; preclinical acceptable. |
| Small-Molecule Weight Loss (energy expenditure) | Oral-preferred small molecules that drive weight loss via energy metabolism / expenditure (not appetite suppression); preclinical acceptable. |
| Rare/Special Movement Disorders, MND, Rare Epilepsy | Disease-modifying programs for rare/special movement disorders, motor neuron disease, or rare epilepsy; any stage; modality open. |
| TRAIL Agonist | TRAIL-agonist programs from PCC through Phase II; indication flexible. |
| siRNA / ASO / Small Nucleic Acid (fund) | Oligonucleotide and small-nucleic-acid programs - siRNA, antisense, small nucleic acids; any disease area; preclinical acceptable. |
| Cardiovascular & Kidney Disease | CV and renal programs - small molecule, large molecule, siRNA, peptide, or antisense; preclinical acceptable. |
| KRAS G12V (Oncology) | KRAS G12V-targeted programs, small molecule or biologic, IND-cleared or later; ex-China / global rights. |
| AL Amyloidosis | Programs for AL amyloidosis at PCC stage or later; small molecule or biologic; mechanism open. |
| ANCA-Associated Vasculitis | Programs addressing GPA, MPA, or EGPA at PCC stage or later; small molecule or biologic. |
| Anemia of CKD | Programs for anemia of chronic kidney disease at PCC stage or later; small molecule or biologic. |
| Anemia of IBD | Programs for anemia of inflammatory bowel disease at PCC stage or later; small molecule or biologic. |
| CCR3 Antagonist | CCR3 antagonist programs; preclinical acceptable; indication flexible. |
| JAG1 Agonist | JAG1 (Jagged-1) agonist programs; preclinical acceptable; indication flexible. |
| ENTPD1 / CD39 Antagonist | ENTPD1 (CD39) antagonist programs; preclinical acceptable; immuno-oncology focus. |
| Fund - China Phase I/IIa geographic-arbitrage | Chinese sponsor with a clean Phase I or IIa readout, open to a Western development plan; fund leads EU/US clinical work and downstream MNC out-license. |
| Fund - Newco around Phase III asset | Late-stage (Ph III) programs in Oncology, Autoimmune, or CNS where the originator is open to a fund-backed Newco. |
Featured License-Out
A China-based biotech is seeking global partners for a first-in-class (FIC) immunotherapy platform targeting autoimmune diseases. The platform is built on a proprietary antigen-specific tolerance technology designed to modulate immune response without systemic immunosuppression - a mechanism that, if validated, would directly address the central limitation of currently marketed biologics in this space.
| Attribute | Detail |
|---|---|
| Opportunity Type | License-Out - global partnership sought |
| Originator | China-based biotech (fully integrated; R&D, clinical, manufacturing, global supply chain) |
| Platform | First-in-class (FIC) immunotherapy platform based on proprietary antigen-specific tolerance technology. Designed to modulate the immune response without systemic immunosuppression. |
| Lead Asset - Stage | Phase II in Graves' disease (GD) |
| Additional Indications | Thyroid eye disease (TED) - Multiple sclerosis (MS) - Type 1 diabetes (T1D) |
| Clinical Readouts to Date | Safety: no severe AEs in Phase I. Efficacy: meaningful reduction in disease biomarkers. Mechanism benefit: potential for long-term disease remission via immune-tolerance induction. |
| IP Position | >150 granted patents; multiple FIC assets in the pipeline |
| Deal Type Sought | Global partnership / out-license discussions (ex-China rights negotiable) |
| Contact | BD@biorichinc.com (direct message also welcome) |
The lead asset is Phase II and the platform produces multiple FIC programs in autoimmune disease - squarely within the autoimmune mandate from Western buyers. For the geographic-arbitrage fund model, the Phase II GD program could also serve as a candidate for a Western Phase II/III re-read with fund capital, particularly given the clean Phase I safety profile.
Services & Capital - Standing
Beyond asset licensing, two standing service and capital offerings remain open. These are not drug-licensing deals and are listed here rather than on the Licensing Opportunities page.
ADC CDMO - Services in Exchange for Equity
An ADC-focused contract development and manufacturing organization (CDMO) is offering its services in exchange for equity, supporting ADC companies that need development and manufacturing capacity. ADC companies with such needs are welcome to make contact.
ADC Investment Mandate - Chinese ADC Developers
An investor is looking to invest in Chinese ADC (antibody-drug conjugate) drug-development companies. Each investment is USD 2-3M, with a preference for ADC projects that are close to entering the CMC stage.
Contact & Submissions
- To submit assets matching any mandate above: BD@biorichinc.com (include modality, stage, last clinical readout, and territory availability).
- Browse the full, filterable opportunity set - including out-licensing assets - on the Licensing Opportunities page.
- Role cross-reference - see Section 3 (Job Postings) for BD&L professionals available for hire (VP BD, licensing counsel).
BioLink Weekly - Section 4, BD&L Opportunity Board. Prepared June 23, 2026. Buyer and fund mandates are summarized from direct briefings; specific terms available upon NDA. Deal terms and clinical figures elsewhere in this issue are drawn from company press releases and named reputable sources; unverifiable items were omitted.
BioLink Weekly is published by BioRich International, Princeton NJ.
lisa.fan@biorichinc.com